康复新液联合胶体果胶铋兰索拉唑四联治疗难治性消化性溃疡的临床观察

目的探讨康复新液联合胶体果胶铋兰索拉唑四联疗法治疗难治性消化性溃疡的临床疗效。方法将湖南省耒阳市人民医院自2009年8月～2010年8月收治的72例确诊难治性消化性溃疡的患者随机分为两组。对照组患者给予兰索拉唑片、胶体果胶铋混悬剂、阿莫西林胶囊,奥硝唑分散片,7d后兰索拉唑继续治疗至1个月;实验组患者在此基础上增加康复新液的治疗,1个月后比较两组患者的临床疗效,对于两组中痊愈的患者于1年后比较其复发率。结果实验组患者的痊愈率及复发率分别为55.6%和15.0%,而对照组患者的痊愈率及复发率分别为33.3%和41.7%,实验组的痊愈率显著高于对照组(P<0.05),实验组的复发率显著低于对照组(P<0.05)。结论康复新液联合胶体果胶铋兰索拉唑四联疗法对于治疗难治性消化性溃疡具有良好的临床疗效,且能够降低复发率,值得临床推广应用。

Objective To investtigate the clinical efficacy of kangfuxin liquid joint guojiaobi lansoprazole quadruple therapy in the treatment of the refractory peptic ulcer. Methods From August 2009 to August 2010, 72 cases of refractory peptic ulcers were confirmed and treated in our hospital, which were randomLy divided into experimental group and control group. The patients of control group were treated by lansoprazole and amoxicillin treatment, while patients of experimental group were given the treatment of kangfuxin liquid in addition. Then compare the clinical efficacy of two groups after one month＇s treatment, and the the relapse rate of patients who recovered in a month 1 year later. Results The cure rate and relapse rate of the experimental group patients were 55.6%, 15.0%, while The cure rate and relapse rate of the control group were 33.3%, 41.7%. The cure rate of the experimental group was significantly higher （P 〈 0.05 ）, and the relapse rate of the experimental group was significantly lower than the control group （P〈0.05）. Conclusion The kangfuxin liquid joint lansoprazole triple therapy not only has better clinical efficacy for refractory peptic ulcer, but also can reduce the relapse rate, which is worthy of clinical application.